Stavanger Universitetssykehus
Stavanger, Norway
5 recruiting
Showing 1–6 of 6 trials
Recruiting
Phase 3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
Carcinoma, Non-Small Cell LungNeoplasm Metastasis
Eli Lilly and Company1,264 enrolled420 locationsNCT06119581
Recruiting
Phase 3
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
Ovarian NeoplasmsNeoplasm MetastasisFallopian Tube Neoplasms+1 more
Eli Lilly and Company1,630 enrolled261 locationsNCT07213804
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults
Diabetes Mellitus, Type 1
Eli Lilly and Company150 enrolled107 locationsNCT07222137
Recruiting
Phase 3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
Diabetes Mellitus, Type 1
Eli Lilly and Company300 enrolled132 locationsNCT07222332
Recruiting
Not Applicable
Personalized Digital Treatment for Adolescent Anxiety: A Feasibility Trial
Anxiety Disorders
Helse Stavanger HF46 enrolled2 locationsNCT07145307
Recruiting
Not Applicable
Palliative Radiotherapy in Symptomatic Pelvic Soft Tissue Tumors
Gynecologic CancerUrologic CancerGastrointestinal Cancer
Sykehuset Telemark200 enrolled11 locationsNCT06398314